Completed PHASE2 INTERVENTIONAL 4-arm NCT00113893

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

A Randomized, MultiCenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients With Myelodysplastic Syndromes

Sponsor: Scios, Inc.

Conditions Bone Marrow Diseases Bone Marrow Neoplasms Hematologic Diseases Myelodysplastic Syndromes

Interventions SCIO-469

Updated 7 times since 2017 Last updated: Oct 15, 2013 Started: May 31, 2005 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Bone Marrow Diseases and Bone Marrow Neoplasms, this trial is completed. The trial is conducted by Scios, Inc. and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Scios, Inc.

Data source: Scios, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.